Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations.

Autor: Wierda WG; MD Anderson Cancer Center, Houston, TX, USA. wwierda@mdanderson.org., Rawstron A; Haematological Malignancy Diagnostic Service, Leeds, UK., Cymbalista F; Hôpital Avicenne, AP-HP, UMR Université Paris13/INSERM U978, Bobigny, France., Badoux X; The St. George Hospital, Sydney, NSW, Australia., Rossi D; Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland., Brown JR; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA., Egle A; Department of Internal Medicine III with Haematology, Medical Oncology, Hemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Cancer Cluster Salzburg, Salzburg, Austria., Abello V; Hospital de San José, Bogota, Colombia., Cervera Ceballos E; Instituto Nacional de Cancerologia/Médica Sur Fundación Clínica, Mexico City, Mexico., Herishanu Y; Tel-Aviv Sourasky Medical Center and Sackler Medical School, Tel Aviv, Israel., Mulligan SP; Royal North Shore Hospital, Sydney, NSW, Australia., Niemann CU; Rigshospitalet, Copenhagen, Denmark., Diong CP; Parkway Cancer Centre, Singapore, Singapore., Soysal T; Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey., Suzuki R; Shimane University Hospital, Shimane, Japan., Tran HTT; Akerhus University Hospital, Lørenskog, Norway., Wu SJ; National Taiwan University Hospital, Taipei, Taiwan., Owen C; Tom Baker Cancer Centre, Calgary, AB, Canada., Stilgenbauer S; Internal Medicine III, Ulm University, Ulm and Internal Medicine 1, Saarland University, Homburg, Germany., Ghia P; Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy., Hillmen P; Leeds Teaching Hospitals, NHS Trust, Leeds, UK.
Jazyk: angličtina
Zdroj: Leukemia [Leukemia] 2021 Nov; Vol. 35 (11), pp. 3059-3072. Date of Electronic Publication: 2021 Jun 24.
DOI: 10.1038/s41375-021-01241-1
Abstrakt: Assessment of measurable residual disease (often referred to as "minimal residual disease") has emerged as a highly sensitive indicator of disease burden during and at the end of treatment and has been correlated with time-to-event outcomes in chronic lymphocytic leukemia. Undetectable-measurable residual disease status at the end of treatment demonstrated independent prognostic significance in chronic lymphocytic leukemia, correlating with favorable progression-free and overall survival with chemoimmunotherapy. Given its utility in evaluating depth of response, determining measurable residual disease status is now a focus of outcomes in chronic lymphocytic leukemia clinical trials. Increased adoption of measurable residual disease assessment calls for standards for nomenclature and outcomes data reporting. In addition, many basic questions have not been systematically addressed. Here, we present the work of an international, multidisciplinary, 174-member panel convened to identify critical questions on key issues pertaining to measurable residual disease in chronic lymphocytic leukemia, review evaluable data, develop unified answers in conjunction with local expert input, and provide recommendations for future studies. Recommendations are presented regarding methodology for measurable residual disease determination, assay requirements and in which tissue to assess measurable residual disease, timing and frequency of assessment, use of measurable residual disease in clinical practice versus clinical trials, and the future usefulness of measurable residual disease assessment. Nomenclature is also proposed. Adoption of these recommendations will work toward standardizing data acquisition and interpretation in future studies with new treatments with the ultimate objective of improving outcomes and curing chronic lymphocytic leukemia.
(© 2021. The Author(s).)
Databáze: MEDLINE
Externí odkaz: